Jintanat Ananworanich

Summary

Affiliation: Chulalongkorn University
Country: Thailand

Publications

  1. doi request reprint Incidence and characterization of acute HIV-1 infection in a high-risk Thai population
    Jintanat Ananworanich
    Department of Retrovirology, The Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    J Acquir Immune Defic Syndr 49:151-5. 2008
  2. ncbi request reprint Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration
    Pediatr Infect Dis J 24:874-9. 2005
  3. ncbi request reprint A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 10:761-7. 2005
  4. ncbi request reprint Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    J Acquir Immune Defic Syndr 39:523-9. 2005
  5. ncbi request reprint No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells/mm3
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Colaboration, Thailand
    Asian Pac J Allergy Immunol 23:23-8. 2005
  6. ncbi request reprint Interrupting highly active antiretroviral therapy in patients with HIV
    Jintanat Ananworanich
    The HIV Netherlands, Australia, Thailand Research Collaboration HIV NAT and The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Expert Rev Anti Infect Ther 3:51-60. 2005
  7. ncbi request reprint Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration and the Thai Red Cross AIDS Research Center, Bangkok, Thailand
    AIDS 19:185-92. 2005
  8. ncbi request reprint Immunization for persons infected with human immunodeficiency virus
    Chitsanu Pancharoen
    Infectious Disease Unit, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Thailand
    Curr HIV Res 2:293-9. 2004
  9. ncbi request reprint Creation of a drug fund for post-clinical trial access to antiretrovirals
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Pathumwan, Bangkok 10330, Thailand
    Lancet 364:101-2. 2004
  10. ncbi request reprint Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection
    Jintanat Ananworanich
    Human Immunodeficiency Virus Netherlands Australia Thailand Research Collaboration and Thai Red Cross Acquired Immunodeficiency Syndrome Research Center, Pathumwan, Bangkok, Thailand 10330
    Clin Infect Dis 37:723-5. 2003

Collaborators

Detail Information

Publications38

  1. doi request reprint Incidence and characterization of acute HIV-1 infection in a high-risk Thai population
    Jintanat Ananworanich
    Department of Retrovirology, The Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    J Acquir Immune Defic Syndr 49:151-5. 2008
    ..The objective of this study was to investigate the incidence, demographics, HIV subtype, and genotypic resistance of acute HIV infections in a high-risk Thai population...
  2. ncbi request reprint Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration
    Pediatr Infect Dis J 24:874-9. 2005
    ..To assess the pharmacokinetics and 24-week efficacy and safety of dual boosted saquinavir/lopinavir/ritonavir combination in children...
  3. ncbi request reprint A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 10:761-7. 2005
    ....
  4. ncbi request reprint Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    J Acquir Immune Defic Syndr 39:523-9. 2005
    ..To assess the safety of 2 intermittent treatment strategies compared with continuous therapy for patients with virologic suppression on highly active antiretroviral therapy (HAART) at baseline...
  5. ncbi request reprint No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells/mm3
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Colaboration, Thailand
    Asian Pac J Allergy Immunol 23:23-8. 2005
    ..The eosinophil count was higher after IL-2 administration. It was concluded that IL-2 plus ARV resulted in higher CD4 counts but had no effect on atopy...
  6. ncbi request reprint Interrupting highly active antiretroviral therapy in patients with HIV
    Jintanat Ananworanich
    The HIV Netherlands, Australia, Thailand Research Collaboration HIV NAT and The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Expert Rev Anti Infect Ther 3:51-60. 2005
    ....
  7. ncbi request reprint Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration and the Thai Red Cross AIDS Research Center, Bangkok, Thailand
    AIDS 19:185-92. 2005
    ..To determine the incidence and risk factors for rash in Thai patients taking four different non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens...
  8. ncbi request reprint Immunization for persons infected with human immunodeficiency virus
    Chitsanu Pancharoen
    Infectious Disease Unit, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Thailand
    Curr HIV Res 2:293-9. 2004
    ..Vaccine trial in HIV-infected patients is needed in order to establish the most appropriate vaccine recommendation for this group of patients...
  9. ncbi request reprint Creation of a drug fund for post-clinical trial access to antiretrovirals
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Pathumwan, Bangkok 10330, Thailand
    Lancet 364:101-2. 2004
  10. ncbi request reprint Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection
    Jintanat Ananworanich
    Human Immunodeficiency Virus Netherlands Australia Thailand Research Collaboration and Thai Red Cross Acquired Immunodeficiency Syndrome Research Center, Pathumwan, Bangkok, Thailand 10330
    Clin Infect Dis 37:723-5. 2003
    ..All 3 patients had slightly low or normal platelet counts before initiating antiretroviral therapy. STI may play a role in inducing thrombocytopenia in patients with human immunodeficiency virus infection...
  11. ncbi request reprint Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease
    Sanneke Koekkoek
    Department of Clinical Neuropsychology, Faculty of Social Sciences, VU University, Van der Boechorststraat 1, 1081 BT, Amsterdam, The Netherlands
    J Neurol 253:1615-24. 2006
    ..This study assesses the effects of HAART on psychomotor performance of symptomatic HIV-infected children. It is one of the first studies to look at neurobehavioral functioning in children infected with HIV in resource-limited countries...
  12. pmc Lessons from a multicentre paediatric HIV trial
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Pathumwan, Bangkok, Thailand 10330
    Lancet 372:356-7. 2008
  13. ncbi request reprint Intermittent therapy for the treatment of chronic HIV infection
    Jintanat Ananworanich
    AIDS 21:123-34. 2007
  14. ncbi request reprint Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens
    Stephen J Kerr
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 6:36-46. 2007
    ..Non-stavudine-containing non-boosted protease-inhibitor-based highly active antiretroviral treatment regimens had the least association with dyslipidemia...
  15. doi request reprint Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting
    Somsamorn Mangclaviraj
    Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Int J STD AIDS 19:529-32. 2008
    ..In settings where access to affordable treatment is improving, this study reinforces the importance of regular Pap smear screening in HIV-positive women, particularly those with low nadir CD4 counts and lower incomes...
  16. ncbi request reprint Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 13:375-80. 2008
    ..The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs)...
  17. ncbi request reprint No change in calculated creatinine clearance after tenofovir initiation among Thai patients
    Angele Gayet-Ageron
    University Hospital of Geneva, Geneva, Switzerland
    J Antimicrob Chemother 59:1034-7. 2007
    ..We asked the question whether this higher per kilogram dose was associated with more nephrotoxicity...
  18. ncbi request reprint Antiretroviral therapy adherence did not differ between Thai children with biological and those with nonbiological parents
    Kelly Safreed-Harmon
    Clin Infect Dis 45:669-70. 2007
  19. ncbi request reprint Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease
    Lai Kim Leng
    University of Malaya, Kuala Lumpur, Malaysia
    J Med Assoc Thai 90:1937-42. 2007
    ..This report documents a case of infiltrating cervical spinal mass, most likely a spinal tumor, in a girl with HIV infection that regressed following HAART and without treatment of the tumor or any anti-infectives...
  20. doi request reprint Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks
    Pope Kosalaraksa
    Khon Kaen University, Khon Kaen, Thailand
    Pediatr Infect Dis J 27:623-8. 2008
    ....
  21. ncbi request reprint Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection
    Reto Nuesch
    HIV NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    AIDS 22:152-4. 2008
    ..Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted...
  22. ncbi request reprint Incidence and risk factors for non-nucleoside reverse transcriptase inhibitors (NNRTI)-related rash in Thai children with HIV infection
    Sunitha Vemula
    Washington University, St Louis, USA
    J Med Assoc Thai 90:2437-41. 2007
    ..The only significant predictive factor that correlated with the development of NNRTI-related rash in a multivariate logistic regression model was a CD4% decrease at week 12...
  23. doi request reprint Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Antimicrob Chemother 61:1340-3. 2008
    ..Here, we evaluated the effect of switching from stavudine/didanosine to tenofovir/lamivudine on measures of metabolic and mitochondrial toxicity in Thai patients...
  24. ncbi request reprint Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 11:631-5. 2006
    ..There are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r), particularly in antiretroviral (ARV)-naive patients...
  25. ncbi request reprint Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand
    Reto Nuesch
    HIV Netherlands Australia Thailand Research Collaboration and the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Antimicrob Chemother 58:637-44. 2006
    ..Time-dependent occurrence of grade III/IV abnormal laboratory values as defined by the AIDS Clinical Trial Group was analysed...
  26. ncbi request reprint In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy
    Jintanat Ananworanich
    J Acquir Immune Defic Syndr 32:570-2. 2003
  27. ncbi request reprint Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial
    Jintanat Ananworanich
    HIVNAT The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center
    AIDS 17:F33-7. 2003
    ..A schedule of 1 week on and 1 week off therapy offers the promise of 50% less drug exposure with continuously undetectable HIV RNA concentration...
  28. ncbi request reprint Antiretroviral therapy-related hyperlactatemia
    Jintanat Ananworanich
    Pediatr Infect Dis J 23:375; author reply 375-6. 2004
  29. ncbi request reprint Undetectable plasma HIV-1 RNA with strong gag-pol specific interferon-gamma ELISPOT response in an HIV-1 clade A/E-infected child untreated with antiretroviral therapy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration and The Thai Red Cross AIDS Research Center, Thailand
    Asian Pac J Allergy Immunol 22:165-9. 2004
    ..0. DNA PCR was positive by methods using gag/pol primers but not env/pol primers. The patient had strong HIV-1-specific cytotoxic T lymphocyte responses, which likely contributed to her low viral burden and undetectable plasma HIV-1 RNA...
  30. ncbi request reprint Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg
    Jintanat Ananworanich
    Antivir Ther 9:1035-6. 2004
  31. ncbi request reprint Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E
    Rangsima Lolekha
    Queen Sirikit National Institute of Child Health
    Clin Infect Dis 40:309-12. 2005
    ..Almost all children had resistance to at least 1 NRTI, and approximately half of the children had resistance to multiple NRTIs. Cross-resistance to stavudine and azidothymidine was universal...
  32. ncbi request reprint A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection
    Peter G Cardiello
    The HIV Netherlands Australia Thailand Research Collaborative, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Clin Infect Dis 40:594-600. 2005
    ....
  33. ncbi request reprint Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment
    Reto Nuesch
    HIV Netherlands, Australia, Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Clin Infect Dis 40:728-34. 2005
    ..One major concern, however, is the development of resistance to antiretroviral drugs that can occur during multiple cycles of starting and stopping therapy...
  34. ncbi request reprint Biphasic decline of CD4 cell count during scheduled treatment interruptions
    Catherine Fagard
    University Hospital, Geneva, Switzerland, and the Swiss HIV Cohort Study
    AIDS 19:439-41. 2005
    ....
  35. ncbi request reprint Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients
    Reshma Saskia Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    J Antimicrob Chemother 56:908-13. 2005
    ..Differential exposure to saquinavir/ritonavir may lead to therapy failure. The objective was to identify factors that influence variability of saquinavir/ritonavir plasma concentrations...
  36. ncbi request reprint CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
    Jintanat Ananworanich
    HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Lancet 368:459-65. 2006
    ..Stopping antiretroviral therapy in patients with HIV-1 infection can reduce costs and side-effects, but carries the risk of increased immune suppression and emergence of resistance...
  37. ncbi request reprint Participation in randomized trials in developing countries
    Wichitra Apateerapong
    J Pediatr 144:140; author reply 140. 2004
  38. ncbi request reprint AIDS orphans
    Jintanat Ananworanich
    N Engl J Med 347:1455-6. 2002